Clinical study

The study suggests people with IBD consumed more dietary emulsifiers than healthy controls and found initial links between higher UPF/emulsifier intake and worse IBD-related events, which could be important if diet...

Fibrostenotic strictures are a major unmet need in Crohn’s disease because anti-inflammatory drugs often cannot reverse established scarring; IL-11 is a biologically plausible target that might selectively affect...

Fatigue is a common, disabling issue in Crohn’s disease with unclear biology. This study suggests measurable brain-structure differences correlate with fatigue severity and may modify how disease activity influences...

IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Probiotics and Antimicrobial Proteins.

FMT is shown here to be an effective option for treating recurrent C. difficile infection, including for patients who also have IBD — a group often vulnerable to recurrent infections and complications.

Researchers and clinicians want biomarkers that predict outcome or tailor treatment. This study suggests a mucosal gene-expression score is prognostic and declines in responders, but it does not yet show the score...

MRE is a widely used, noninvasive test that increasingly helps characterize disease phenotype and prognosis in Crohn's disease and IBD, which can affect monitoring and treatment planning.

The study directly compares fatigue levels across several chronic conditions using the same validated tools, offering context for how fatigue in IBD compares to other illnesses. That context can help patients and...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Archives of medical science : AMS.

For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...

Understanding microbiota–neuroimmune interactions could explain why symptoms like urgency and pain persist in some people with UC and may point to new treatment strategies that go beyond conventional anti-inflammatory...

The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...

This study aims to show how mirikizumab and other biologics perform in everyday community practice — information that can help clinicians and patients understand real-world treatment durability, symptom control, and...

If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...

A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.

Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...

IL-11 is implicated in fibrostenotic Crohn’s disease; determining whether it is a reversible therapeutic target could lead to treatments that prevent or reverse strictures rather than only managing inflammation or...

Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.

The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials.

Findings highlight cultivable gut microbiota differences in Crohn’s disease versus controls and present preliminary in vitro antimicrobial activity of two thyme essential oils—topics that may interest patients following...

Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...

Protein biomarkers that predict IBD years before diagnosis could enable earlier detection, inform risk-stratified monitoring, and reveal early disease pathways that might be targeted to prevent or delay onset.

Diarrhea is a common, burdensome symptom in IBD. This study suggests that inflammation-linked defects in enterocyte differentiation and reduced ion transporter expression may help explain persistent diarrhea and that...

Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...

Intestinal fibrosis can cause strictures and obstructive complications that often lead to surgery. Research identifying the cellular drivers and druggable pathways could guide development of treatments to prevent or slow...

Fusing blood tests, CT enterography radiomics, and deep-learning analysis of deep small-bowel endoscopy images may improve detection of active small-bowel Crohn’s disease — a common clinical challenge because many...

This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.

Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...

The paper suggests serum bilirubin levels statistically explain a meaningful fraction of the link between gut Enterobacterales abundance and endoscopic disease activity in UC, which may point to biologic pathways or...

The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...

TG2 produced by intestinal myofibroblasts may drive fibrosis and strictures in Crohn's disease independently of inflammation; blocking TG2 reduced fibrosis in lab and mouse models, pointing to a possible new...

This large, long-term study suggests that having pets or farm animals during pregnancy or early childhood probably does not meaningfully change a child’s later risk of developing IBD, which may reassure families...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Digestive and liver...

MASLD was common in this IBD cohort and became more frequent as BMI increased; clinicians and patients may need to consider liver health when managing IBD, especially for people with overweight or obesity.

Earlier identification of people likely to develop IBD could shorten diagnostic delays that are linked to worse outcomes, and an automated EHR model might help target who should get earlier evaluation.

The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.

RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical journal...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Genetics and genomics, and Research and clinical trials. The original article is from Gut.

This trial suggests a structured whole-food diet may reduce subclinical intestinal inflammation (measured by fecal calprotectin) in asymptomatic children and young adults with Crohn's disease—offering a non-formula,...

If true, the finding explains why symptoms can return after remission: the gut lining may remain biologically vulnerable even when inflammation seems controlled. That could point to new approaches aimed at 'molecular...

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.

A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...